Cell and Gene Challenges with AGC Biologics
20 March 2023
Regulatory & Standards
Maggie Chen, Head of Manufacturing at AGC Biologics, explores the challenges within the cell and gene therapy landscape.
In this interview, Maggie initially considers challenges associated with the cost of goods and supply chain, before discussing how standardization will benefit viral vector development.
Maggie goes on to address analytics and bad data as rate limiting factors to the progression of the field, and how a combination of different approaches may be what’s needed to realize the future of cell and gene therapies, before explaining what we might have to look forward to from AGC Biologics.
This interview has been produced in partnership with AGC Biologics and was recorded at Advanced Therapies Week 2023.
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
8 June 2023
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
7 June 2023
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
5 June 2023